Interestingly, the KOR agonist TRK820 (nalfurafine), which has been clinically approved in Japan for use in hemodialysis-related uremic pruritus, could be useful for tumor therapy by suppressing tumor angiogenesis, and thus could offer therapeutic benefits beyond the relief of cancer pain. This evidence concerns the gene OPRK1 and neoplasm.